scholarly journals Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia

2007 ◽  
Vol 45 (11) ◽  
pp. 1527-1529 ◽  
Author(s):  
M. Brisson ◽  
J. M. Pellissier ◽  
M. J. Levin
Keyword(s):  
Herpes Zoster ◽  
Cost Effectiveness ◽  
Postherpetic Neuralgia ◽  
Zoster Vaccine

scholarly journals Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure

2021 ◽  
Author(s):  
Hector S Izurieta ◽  
Xiyuan Wu ◽  
Richard Forshee ◽  
Yun Lu ◽  
Heng-Ming Sung ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Herpes Zoster ◽  
Real World ◽  
Postherpetic Neuralgia ◽  
Vaccine Effectiveness ◽  
Community Dwelling ◽  
Zoster Vaccine ◽  
Post Market ◽  
Recombinant Zoster Vaccine ◽  
Dose Vaccine

Abstract Background Shingrix™ (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed as two doses given 2–6 months apart, among adults ages ≥50 years. Clinical trials yielded efficacy of >90% for confirmed herpes zoster,but post-market vaccine performance has not been evaluated. Efficacy of a single dose, delayed second dose, or among persons with autoimmune or general immunosuppressive conditions have also not been studied. We aimed to assess post-market vaccine effectiveness of Shingrix. Methods We conducted a cohort study among vaccinated and unvaccinated Medicare Part D community dwelling beneficiaries ages >65 years. Herpes zoster was identified using a medical office visit diagnosis with treatment, and postherpetic neuralgia using a validated algorithm. We used inverse probability of treatment weighting to improve cohort balance, and marginal structural models to estimate hazard ratios. Results We found a vaccine effectiveness of 70.1% (95% CI, 68.6–71.5) and 56.9% (95% CI, 55.0–58.8) for two and one doses, respectively. The two-dose vaccine effectiveness was not significantly lower for beneficiaries 80+ years, for second doses received at ≥180 days, or for individuals with autoimmune conditions. The vaccine was also effective among individuals with immunosuppressive conditions. Two-dose vaccine effectiveness against postherpetic neuralgia was 76.0% (95% CI, 68.4-81.8). Conclusions This large real-world observational study of effectiveness of Shingrix demonstrates the benefit of completing the two-dose regimen. Second doses administered beyond the recommended 6 months did not impair vaccine effectiveness.Our effectiveness estimates were lower than the clinical trials estimates, likely due to differences in outcome specificity.

Is herpes zoster vaccine safe and effective for preventing zoster and postherpetic neuralgia?

2015 ◽  
Vol 18 (9) ◽  
pp. 9-10
Author(s):  
Emily Colson ◽  
Aaron TenHarmsel ◽  
Michael D. Geurin
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Zoster Vaccine

scholarly journals Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia: 2014 Update and consensus statement from the Canadian Pain Society

2015 ◽  
Vol 20 (1) ◽  
pp. 46-47 ◽  
Author(s):  
Canadian Pain Society Study Day participants
Keyword(s):  
Herpes Zoster ◽  
Pain Management ◽  
Advisory Committee ◽  
Postherpetic Neuralgia ◽  
Consensus Statement ◽  
Position Statement ◽  
Zoster Vaccine

The Canadian Pain Society (CPS) hosted its first Study Day in Toronto in July 2014, attended by experts in various fields of pain management and research (listed below). The aim was to review the National Advisory Committee on Immunization guidelines and to prepare a CPS position statement concerning the use of the zoster vaccine in Canada.

scholarly journals Cost-effectiveness of Vaccination Against Herpes Zoster and Postherpetic Neuralgia: A Critical Review

2013 ◽  
Vol 16 (7) ◽  
pp. A334
Author(s):  
K. Kawai ◽  
E. Préaud ◽  
F. Baron-Papillon ◽  
C.J. Acosta
Keyword(s):  
Herpes Zoster ◽  
Cost Effectiveness ◽  
Postherpetic Neuralgia ◽  
Critical Review

Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years

2015 ◽  
Vol 163 (7) ◽  
pp. 489 ◽  
Author(s):  
Phuc Le ◽  
Michael B. Rothberg
Keyword(s):  
Herpes Zoster ◽  
Cost Effectiveness ◽  
Zoster Vaccine
Sign in / Sign up

Export Citation Format

Share Document